OTLK: Outlook Therapeutics, Inc. Stock

by  •  • Comments Off on OTLK: Outlook Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 45.70
Enterprise Value ($M) 60.21
Book Value ($M) -73.08
Book Value / Share -2.93
Price / Book -0.63
NCAV ($M) -74.48
NCAV / Share -2.99
Price / NCAV -0.61

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -3.48
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.64
Current Ratio 0.64

Balance Sheet (mrq) ($M)
Current Assets 27.42
Assets 28.82
Liabilities 101.90
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -71.70
Net Income -75.37
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -68.79
Cash from Investing 0.00
Cash from Financing 60.33

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-22 13D/A GMS Ventures & Investments
11-14 13G/A Great Point Partners Llc 9.99 11.23
11-07 13G/A Velan Capital Investment Management LP 3.10 -40.00
04-17 13D/A Syntone Ventures LLC 11.40 -85.99
03-28 13G Tang Capital Partners Lp 9.99
2024-01-31 13D/A BioLexis Pte Ltd. 6.40 -14.03

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-01-23 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2024 ☐TRANSITION REPOR
2024-12-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 229,483 560,641 40.93
2025-02-03 490,504 1,339,560 36.62
2025-01-31 385,621 1,133,972 34.01
2025-01-30 118,511 437,906 27.06

(click for more detail)

Similar Companies
ONVO – Organovo Holdings, Inc. ORGO – Organogenesis Holdings Inc.
ORMP – Oramed Pharmaceuticals Inc. PALI – Palisade Bio, Inc.
PCSA – Processa Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io